anna bucsics presentation

8/14/2019 Anna Bucsics Presentation

http://slidepdf.com/reader/full/anna-bucsics-presentation 1/16

1

Seite 1 2012 M A . A S S I H T A W E 2012 P 1

A

A B , H S

D P A A A


A

T D

P A , MEDEV C ,

EU HTA .T .

S E S



2

2012 M A . A S S I H T A W E 2012 P 3

.

,

, .

D


T B



3


O D C

• RARITY ( ) M 5 10,000 C ( 250,000)

OR

• RETURN ON INVESTMENT: W

• SERIOUSNESS: L

• ALTERNATIVE METHODS AUTHORISED

• I

F :// . . . / / GB/ /P /2011/06/WC500107046.


W ?

P

. R

,

.

P M O C EH C . W , B H , 7. O 2010



4

2012 M A . A S S I H T A W E 2012 P 7

A , , ‖

BIOMARKERS DEFINITIONS WORKING GROUP:BIOMARKERS AND SURROGATE ENDPOINTS: PREFERREDDEFINITIONS AND CONCEPTUAL FRAMEWORK.CLIN PHARMACOL THER 2001;69:89 95.

B D


B E F

•B :

( );• B :

;• B :

,

;• B :

.

R M : :// . / / /D

Maraviroc: Before taking CELSENTRI it has to beconfirmed thatonly CCR5-tropic HIV-1is detectable(i.e. CXCR4 or dual/mixed tropic virus not detected)

using an adequately validated and sensitive detectionmethod on a newly drawn blood sample. The

Monogram Trofile assay was used in the clinicalstudies of CELSENTRI […] Other phenotypic and

genotypic assays are currently being evaluated.

C C:ObjectiveResponse Rate for EGFR-mutation positive patients:71% Objective ResponseRate for EGFR-mutationnegative patients: 1%

A :LA-B*5701BUTIn any patient treatedwith abacavir, theclinical diagnosis ofsuspectedhypersensitivity reactionmust remain the basis ofclinical decision-making



5


A C

.

,

,1 , 0 .1

I H B E R MSG ., N E J M 2012; 366:883 892,M 8, 2012,DOI:10.1056/NEJM 1113205


B

• P :• M A• T D (89/105/EWG)

• N R• D :

• M D D (93/42/EEC)• N R



6


C D 89/105/EEC 21 D 1988

• L S : D , I C E C

• S : D

• C : D : – T ( 90 + 90 )

– B & – T


C D 93/42/EEC 14 1993

• D • P • C

• N ... T D ,



7


THE FOURTH HURDLE

A• Q• E• S

E

• W

?• I

?• I

?

A .

2012 M A . A S S I H T A W E 2012 P 14

D C

1. H P C U T2. D T C

T3. C E

4. S5. C E

E E6. E A7. O A8. S A9. L A . .

. .



8


A

R A• A

• U , T

D

F A• R

• R

• L

2012 M A . A S S I H T A W E 2012 P 16

• I ?• ,

• I / ?• ,

• I / ?

• ;

• N , ?• ,

• S •



9


D E

C D

M 1 251

M 32 242

M 407 631

E E : 2010 2020 O J RD 2011, 6:62 :10.1186/1750 1172 6 62, C S ( @ . ), T M( @ . ), A H ( @ . )

2012 M A . A S S I H T A W E 2012 P 18

• P O M • T .

A C . A D A 2011 A C . A D A 2011

20,90 2.698,96

Loss of orphan status – orphan price remains…



10


P

• C

,

• ,

• , ,

.

• R

• D • R O : A

O D L 2001, E 377 , 500


C A

• F : P C R P

•

– WP1: / – WP2: M – WP3:T ( )

• :DG ENT, MS (P , P , P ), EMIN



11


FC D D D

E( . 500 000 000)

25 000 250 000 2 500 25 000 2 500

AA / ,

( )

,

,

E ,D B(C , ,

. . )

,

( )

<30% 30 60% >60%

D C(D )


D : ? E ?

O J R D 2012, 7:74 :10.1186/1750 1172 7 74, W H W (. @ .), A P( @ . ), A S (AS @ .), S S ( . @ . . )



12


C & C

• M C• C A D &

T D, ,

?

• O• D ,

?

Bi1


C C : C D , D D

• S :C , S P C (SPC)

, (EMA/CHMPEC), , ' ,

( )

. E , .

• V : SPCP SPC

C 21 : D ; SM , H G E , A B , W E H L L G , SPC ; DOI: 10.1111/ .13652125.2011.03981.



Slide 23

Bi1 Who pays for the test?Helicobacter-Eradicaton & Helicobacter-TestHDL/LDL-Assay and statins

Anna Bucsics, 15/10/2012



13


Challenges to Estimating Efficiency of

Personalised Medicines C D :

• U ,

• S

• S

• ( ) , ( )

B B :• V B• W /

?

• H ?


E ( ) C

• S • B ?• L ?

• H ?

• A ?• U



14


B ?

• C (X ): C $116.000 US

• I 3 7% ALK+ N S C L C

• T . $250 $1.500 P


V Z

5.1 D B AF

Vemurafenib isindicated in mono-therapy for the treat-ment of adult patientswith BRAF V600mutation-positiveunresectable or meta-static melanoma (seesection 5.1).

.

Before taking vemurafenib, patients must haveBRAF V600 mutation-positive tumour statusconfirmed by a validated test. In the phase II andphase III clinical trials, eligible patients wereidentified using a real-time polymerase chainreaction assay (the cobas 4800 BRAF V600Mutation Test). This test has CE marking and isused to assess the BRAF mutation status of DNAisolated from formalin-fixed, paraffin-embedded(FFPE) tumour tissue.

Costs: Ca. €100.000per patientper year*

*S A J 2012S PC




...T !

anna bucsics presentation

Documents